Company intelligence / Profile preview

Topelia

Five Dock (Sydney), New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Topelia is advancing TPL101, a proprietary fixed-dose antiviral triple therapy (ivermectin + doxycycline + zinc) for COVID-19. The company has completed earlier clinical work and is progressing towards a Phase 3 clinical trial, targeting Australian TGA approval in the 2025 calendar year.[1][5]

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Partnerships with world-renowned experts in infectious diseases and antiviral drug development to support development of TPL101 (names not disclosed publicly).[5]

Beyond the preview

Go deeper on Topelia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topelia.

Explore the full profile